Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Breast 2Sarcoma 1Plasma cell 1Myeloid 1Gynecologic 1Genitourinary 1

Conditions

Stomach Neoplasms 1Sarcoma 1Lung Neoplasms 1Liposarcoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Transitional Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

pembrolizumab 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Cyclophosphamide 5Radiosurgery 3Oncolytic Virotherapy 3Nivolumab 3Injections 3Gemcitabine 3Drug Therapy 3Biopsy 3fludarabine 2belinostat 2Riluzole 2Paclitaxel 2Ipilimumab 2Filgrastim 2Docetaxel 2Cisplatin 2Celecoxib 2Carboplatin 2Bortezomib 2Blood Specimen Collection 2Amifostine 2AH 111585 2tislelizumab 1spartalizumab 1seribantumab 1selpercatinib 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × pemigatinib × Sarcoma × Clear all
NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
30 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡